Screener
Veracyte VCYT Business Segments — Sales & Marketing
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Gross profit | 101,159 | 79,508 |
| Operating expenses: | ||
| Research and development | 27,098 | 17,720 |
| Selling and marketing | 27,156 | 24,454 |
| General and administrative | 23,680 | 33,808 |
| Intangible asset amortization - operating expenses | 579 | 622 |
| Total operating expenses | 78,513 | 76,604 |
| Income from operations | 22,646 | 2,904 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's business segments — sales & marketing?
- Veracyte (VCYT) reported business segments — sales & marketing of $27.16M in Q1 2026.
- How has Veracyte's business segments — sales & marketing changed year-over-year?
- Veracyte's business segments — sales & marketing increased by 11.0% year-over-year, from $24.45M to $27.16M.
- What is the long-term trend for Veracyte's business segments — sales & marketing?
- Over 3 years (2022 to 2025), Veracyte's business segments — sales & marketing has grown at a 0.9% compound annual growth rate (CAGR), from $97.56M to $100.17M.
- What does business segments — sales & marketing mean?
- The aggregate expenditure dedicated to promoting, distributing, and selling the segment's products or services. This metric is essential for assessing the segment's customer acquisition efficiency and market penetration strategy.
Ask your AI about Veracyte's business segments — sales & marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude